Warmuth Markus's Form 4 filing
Monte Rosa Therapeutics, Inc. (GLUE) · filed Jan 9, 2026
- Accession no.
- 0001193125-26-008902
- Filed
- Jan 9, 2026
- Trade date
- Jan 7, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $128.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Warmuth MarkusCIK 0001855643 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 7, 2026 | Common Stock | SSaleDisposed | −3,707 | $23.24 | −$86,150.68 | 620,696 | Direct | |
| Jan 7, 2026 | Common Stock | SSaleDisposed | −1,450 | $23.88 | −$34,626 | 619,246 | Direct | |
| Jan 7, 2026 | Common Stock | SSaleDisposed | −309 | $24.57 | −$7,592.13 | 618,937 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.